Next Science Completes $50M Asset Sale, Eyes $30M Return to Shareholders

Asset Sale Completion Marks Major Shift

On 15 September 2025, Next Science Limited (ASX – NXS) announced the completion of the sale of substantially all its assets to OSARTIS GmbH for a total consideration of US$50 million. This transaction represents a significant milestone for the Sydney-based medical technology company, which has focused on its proprietary XBIO™ technology aimed at combating biofilm-based infections.

The deal includes the transfer of Next Science’s patent-protected intellectual property and related assets, effectively marking a strategic exit from its core operations. The buyer, OSARTIS GmbH, a portfolio company of Demetra Holding S.p.A, will assume certain agreed liabilities as part of the transaction.

Financial Implications and Shareholder Returns

Following repayment of debt, transaction costs, potential tax liabilities, and winding down expenses, Next Science estimates net proceeds of approximately US$30 million. The company intends to return these funds to shareholders, subject to final tax and legal advice. To facilitate this, Next Science will convene a shareholder meeting, expected in November 2025, to seek approval for the proposed distribution method.

This move signals a clear focus on maximising shareholder value from the asset sale, while carefully managing the complexities of tax and regulatory compliance. The transitional service agreements in place until the end of 2025 aim to ensure a smooth handover and operational continuity during the separation period.

Looking Ahead – What This Means for Next Science

Next Science’s decision to divest its core assets and return capital to shareholders raises questions about the company’s future direction. With its proprietary XBIO™ technology now under new ownership, the company’s role will likely shift towards managing the wind-down process and exploring potential new opportunities or restructuring options.

Investors will be watching closely for the outcomes of the upcoming shareholder meeting and any further disclosures regarding tax implications and the timing of distributions. The transaction underscores the evolving landscape of medical technology firms navigating commercialization challenges and capital allocation strategies.